Oligometastatic pulmonary metastasis in pancreatic cancer patients: Safety and outcome of resection
- PMID: 31473583
- DOI: 10.1016/j.suronc.2019.08.010
Oligometastatic pulmonary metastasis in pancreatic cancer patients: Safety and outcome of resection
Abstract
Objective: To assess the perioperative and long-term outcome following pulmonary resection in patients with metachronous metastasis of pancreatic ductal adenocarcinoma (PDAC).
Background: Most patients with PDAC relapse or develop tumor spread to secondary organs. Currently, it remains unclear how to proceed with pulmonary metastasis in the metachronous setting. In particular, the role of surgery remains controversial.
Methods: Data of patients with pulmonary metachronous metastasis after PDAC collected from 2003 to 2015 in databases of two high-volume pancreatic cancer centers were retrospectively analyzed. Clinical and pathological aspects of primary PDAC as well as the perioperative and long-term outcome following pulmonary metastasectomy (PM) was evaluated, respectively. Patients with synchronous liver metastasis or metastasis to other secondary organs were excluded. Univariate survival analysis was performed.
Results: We identified 15 patients undergoing pulmonary resection for suspected metastasis after primary pancreatic resection. Operative and histopathologic evaluation revealed resectable pancreatic pulmonary metastasis in 11 patients (73.3%). The median disease-free survival (DFS) and overall survival (OS) after PM diagnosis was 18 months and 26 months, respectively. The median time to metachronous metastasis (TMM) was 17 months [3-64 months]. Perioperative morbidity was low with only one readmission (8.3%). There was no perioperative mortality. Patients who developed pulmonary metastasis later than 17 months after primary surgery showed better OS compared to those who did earlier (32.2 vs. 14.75 months, p = 0.025). In addition, patients with high-grade tumors had worse survival (12.4 vs. 31 months, p = 0.02). Elevated serum CEA levels or CA 19-9 levels were also not associated with shortened OS.
Conclusions: This study suggests that pulmonary metastasectomy after PDAC is safe and effective. Patients with extended DFS after primary pancreatic surgery as well as favorable tumor grading seem to particularly benefit from pulmonary surgery.
Keywords: Lung metastasis; Pancreatic ductal adenocarcinoma; Pulmonary metastasis; Recurrence; Survival.
Copyright © 2019. Published by Elsevier Ltd.
Similar articles
-
Isolated pulmonary recurrence after resection of pancreatic cancer: the effect of patient factors and treatment modalities on survival.HPB (Oxford). 2019 Aug;21(8):998-1008. doi: 10.1016/j.hpb.2018.12.002. Epub 2019 Feb 15. HPB (Oxford). 2019. PMID: 30777697
-
Resection of pancreatic ductal adenocarcinoma with synchronous distant metastasis: is it worthwhile?World J Surg Oncol. 2014 Nov 18;12:347. doi: 10.1186/1477-7819-12-347. World J Surg Oncol. 2014. PMID: 25407113 Free PMC article.
-
Preoperative evaluation of pancreatic ductal adenocarcinoma with synchronous liver metastasis: Diagnosis and assessment of unresectability.World J Gastroenterol. 2016 Dec 7;22(45):10024-10037. doi: 10.3748/wjg.v22.i45.10024. World J Gastroenterol. 2016. PMID: 28018110 Free PMC article.
-
Surgery for synchronous and metachronous single-organ metastasis of pancreatic cancer: a SEER database analysis and systematic literature review.Sci Rep. 2020 Mar 10;10(1):4444. doi: 10.1038/s41598-020-61487-0. Sci Rep. 2020. PMID: 32157155 Free PMC article.
-
A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.Acta Gastroenterol Belg. 2017 Oct-Dec;80(4):451-461. Acta Gastroenterol Belg. 2017. Retraction in: Acta Gastroenterol Belg. 2018 Apr-Jun;81(2):358. PMID: 29560639 Retracted. Review.
Cited by
-
Locoregional Treatment of Metastatic Pancreatic Cancer Utilizing Resection, Ablation and Embolization: A Systematic Review.Cancers (Basel). 2021 Mar 31;13(7):1608. doi: 10.3390/cancers13071608. Cancers (Basel). 2021. PMID: 33807220 Free PMC article. Review.
-
Anatomical and Biological Considerations to Determine Resectability in Pancreatic Cancer.Cancers (Basel). 2024 Jan 23;16(3):489. doi: 10.3390/cancers16030489. Cancers (Basel). 2024. PMID: 38339242 Free PMC article. Review.
-
Prognostic Analysis of Different Metastatic Patterns in Invasive Intraductal Papillary Mucinous Neoplasm: A Surveillance, Epidemiology, and End Results Database Analysis.Can J Gastroenterol Hepatol. 2021 Dec 23;2021:4350417. doi: 10.1155/2021/4350417. eCollection 2021. Can J Gastroenterol Hepatol. 2021. PMID: 35047460 Free PMC article.
-
A population-based study of synchronous distant metastases and prognosis in patients with PDAC at initial diagnosis.Front Oncol. 2023 Jan 26;13:1087700. doi: 10.3389/fonc.2023.1087700. eCollection 2023. Front Oncol. 2023. PMID: 36776324 Free PMC article.
-
Surgery for Oligometastatic Pancreatic Cancer: Defining Biologic Resectability.Ann Surg Oncol. 2024 Jun;31(6):4031-4041. doi: 10.1245/s10434-024-15129-8. Epub 2024 Mar 19. Ann Surg Oncol. 2024. PMID: 38502293 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical